Ulocuplumab (Anti-CXCR4 / CD184)

Synonyms: BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody

Ulocuplumab (Anti-CXCR4 / CD184) is a fully human IgG4 antibody, targeting CXCR4. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. MW: 144.84 KD.

Ulocuplumab (Anti-CXCR4 / CD184)

Purity & Quality Control

Batch: A252301 Purity: 99% Protein concentration: 6.72mg/ml Endotoxin Level: <1EU/mg
99

Choose Selective CXCR Inhibitors

Name Citation CXCR1 CXCR2 CXCR4 CXCR3 Others
WZ811 20
Mavorixafor 0
AMG 487 3
Motixafortide (BL-8040) 0 cyclin-D1,MCL-1,Bcl-2
Navarixin (SCH-527123) 7
MSX-122 1
LY2510924 2
Reparixin (Repertaxin) 24 CXCL8
SB225002 88
Ladarixin 0
SB 265610 1
Balixafortide (POL6326) 0
SX-682 3
TAK-779 0 CCR5
MSX-130 0
MSX-127 0
AZD5069 3
Danirixin (GSK1325756) 2 CXCL8
LIT-927 5 CXCL12
AMD3465 hexahydrobromide 1
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description Ulocuplumab (Anti-CXCR4 / CD184) is a fully human IgG4 antibody, targeting CXCR4. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. MW: 144.84 KD.

Product Details

CAS No. 1375830-34-4
Molecular Weight 144.84 kDa
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.